ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
0 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
574
|
197K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
0 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
574
|
197K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
2 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
574
|
197K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
3 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
574
|
197K
|
3
|
|
ASX - By Stock
|
EIQ |
Re:
Ann: EIQ Investor Presentation updated
|
|
pld89
|
5 |
3.2K |
1 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
5
|
3.2K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
1 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
574
|
197K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
5 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
574
|
197K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
1 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
574
|
197K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
5 |
15/10/23 |
15/10/23 |
ASX - By Stock
|
574
|
197K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
5 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
574
|
197K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
5 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
574
|
197K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
4 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
65
|
24K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
8 |
08/10/23 |
08/10/23 |
ASX - By Stock
|
65
|
24K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
1 |
08/10/23 |
08/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
7 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
65
|
24K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
8 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
65
|
24K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
0 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
65
|
24K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
4 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
1 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
574
|
197K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
4 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
574
|
197K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
2 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
574
|
197K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
pld89
|
574 |
197K |
3 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
574
|
197K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
6 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
4 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
13 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Jane Bell Appointed Chair of Audit and Risk Committee
|
|
pld89
|
65 |
24K |
9 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
65
|
24K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
6 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
$5.10 Bell Potter securities re-rates MSB
|
|
pld89
|
54 |
24K |
5 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
54
|
24K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
4 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
$5.10 Bell Potter securities re-rates MSB
|
|
pld89
|
54 |
24K |
5 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
54
|
24K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
$5.10 Bell Potter securities re-rates MSB
|
|
pld89
|
54 |
24K |
6 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
54
|
24K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
$5.10 Bell Potter securities re-rates MSB
|
|
pld89
|
54 |
24K |
6 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
54
|
24K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
2 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pld89
|
10K |
3.0M |
1 |
15/09/23 |
15/09/23 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2023 Full Year Financial Results Webcast
|
|
pld89
|
60 |
30K |
6 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
60
|
30K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
pld89
|
17K |
6.8M |
7 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Preliminary Final Report including Appendix 4E
|
|
pld89
|
39 |
16K |
3 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
39
|
16K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast CC Transcript 31/8
|
|
pld89
|
73 |
30K |
19 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
73
|
30K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Preliminary Final Report including Appendix 4E
|
|
pld89
|
39 |
16K |
8 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
39
|
16K
|
8
|
|
ASX - By Stock
|
EIQ |
Re:
Ann: Paid Pilot with Australia's Largest Cardiology Provider
|
|
pld89
|
3 |
1.6K |
2 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
3
|
1.6K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Putin needs to go
|
|
pld89
|
1 |
1.1K |
0 |
28/08/23 |
28/08/23 |
ASX - By Stock
|
1
|
1.1K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
pld89
|
907 |
285K |
0 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
907
|
285K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
pld89
|
907 |
285K |
1 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
907
|
285K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
pld89
|
907 |
285K |
10 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
907
|
285K
|
10
|
|